New pill could tame rare hormone disorder
NCT ID NCT05907291
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new oral drug called atumelnant in 38 adults with classic congenital adrenal hyperplasia, a genetic condition causing hormone imbalances. The drug works by blocking a hormone receptor to lower excess adrenal hormones. Researchers measured safety, side effects, and changes in hormone levels over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atumelnant (CRN04894), an oral drug that blocks a hormone receptor to reduce excess adrenal hormones
What this could lead to
If successful, this could lead to a new oral treatment option for congenital adrenal hyperplasia, potentially reducing the need for high-dose steroids.
What could go wrong
This is an early Phase 2 trial with only 38 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Crinetics Study Site
Pasadena, California, 91105, United States
-
Crinetics Study Site
Ann Arbor, Michigan, 48109, United States
-
Crinetics Study Site
Minneapolis, Minnesota, 55454, United States
-
Crinetics Study Site
St Louis, Missouri, 63110, United States
-
Crinetics Study Site
Morehead City, North Carolina, 28557, United States
-
Crinetics Study Site
Cleveland, Ohio, 44195, United States
-
Crinetics Study Site
Philadelphia, Pennsylvania, 19104, United States
-
Crinetics Study Site
East Providence, Rhode Island, 02915, United States
-
Crinetics Study Site
Córdoba, Córdoba Province, 5000, Argentina
-
Crinetics Study Site
Buenos Aires, C1180, Argentina
-
Crinetics Study Site
Curitiba, Paraná, 80030-110, Brazil
-
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, 20231-092, Brazil
-
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, 20551-030, Brazil
-
Crinetics Study Site
Porto Alegre, Rio Grande do Sul, 90410-000, Brazil
-
Crinetics Study Site
Botucatu, São Paulo, 18618-686, Brazil
-
Crinetics Study Site
Ribeirão Preto, São Paulo, 14051-140, Brazil
-
Crinetics Study Site
São Paulo, São Paulo, 04024-002, Brazil
-
Crinetics Study Site
São Paulo, 05403-000, Brazil
-
Crinetics Study Site
Munich, Bavaria, 80336, Germany
-
Crinetics Study Site
Bangalore, Karnataka, 560054, India
-
Crinetics Study Site
Vellore, Tamil Nadu, 632004, India
-
Crinetics Study Site
Naples, 80131, Italy
-
Crinetics Study Site
Roma, 00161, Italy
-
Crinetics Study Site
Rozzano, 20089, Italy
-
Crinetics Study Site
Sheffield, South Yorkshire, S10 2RX, United Kingdom
-
Crinetics Study Site
Coventry, West Midlands, CV22DX, United Kingdom
-
Crinetics Study Site
London, NW1 2PG, United Kingdom